Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Clinical trial NCT00516724 · COMPLETED

Trial details

NCT number: NCT00516724
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Triple Negative Metastatic Breast Cancer Advanced Ovarian Cancer Carboplatin Paclitaxel

Start date: 2007-06-22
Primary completion: 2013-01-04
Enrollment: 189

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.